BACKGROUND: Antipsychotic medications are commonly prescribed to nursing home residents despite their well-established adverse event profiles. Because little is known about their use in Veterans Affairs (VA) nursing homes [ie, Community Living Centers (CLCs)], we assessed the prevalence and risk factors for antipsychotic use in older residents of VA CLCs. METHODS: This cross-sectional study included 3692 Veterans age 65 or older who were admitted between January 2004 and June 2005 to one of 133 VA CLCs and had a stay of ≥90 days. We used VA Pharmacy Benefits Management data to examine antipsychotic use and VA Medical SAS datasets and the Minimum Data Set to identify evidence-based indications for antipsychotic use (eg, schizophrenia, dementia with psychosis). We used multivariable logistic regression and generalized estimating equations to identify factors independently associated with antipsychotic receipt. RESULTS: Overall, 948/3692(25.7%) residents received an antipsychotic, of which 59.3% had an evidence-based indication for use. Residents with aggressive behavior [odds ratio (OR)=2.74, 95% confidence interval (CI), 2.04-3.67] and polypharmacy (9+ drugs; OR=1.84, 95% CI, 1.41-2.40) were more likely to receive antipsychotics, as were users of antidepressants (OR=1.37, 95% CI, 1.14-1.66), anxiolytic/hypnotics (OR=2.30, 95% CI, 1.64-3.23), or drugs for dementia (OR=1.52, 95% CI, 1.21-1.92). Those residing in Alzheimer/dementia special care units were also more likely to receive an antipsychotic (OR=1.66, 95% CI, 1.26-2.21). Veterans with dementia but no documented psychosis were as likely as those with an evidence-based indication to receive an antipsychotic (OR=1.10, 95% CI, 0.82-1.47). CONCLUSIONS: Antipsychotic use is common among VA nursing home residents aged 65 and older, including those without a documented evidence-based indication for use. Further quality improvement efforts are needed to reduce potentially inappropriate antipsychotic prescribing.
BACKGROUND: Antipsychotic medications are commonly prescribed to nursing home residents despite their well-established adverse event profiles. Because little is known about their use in Veterans Affairs (VA) nursing homes [ie, Community Living Centers (CLCs)], we assessed the prevalence and risk factors for antipsychotic use in older residents of VA CLCs. METHODS: This cross-sectional study included 3692 Veterans age 65 or older who were admitted between January 2004 and June 2005 to one of 133 VA CLCs and had a stay of ≥90 days. We used VA Pharmacy Benefits Management data to examine antipsychotic use and VA Medical SAS datasets and the Minimum Data Set to identify evidence-based indications for antipsychotic use (eg, schizophrenia, dementia with psychosis). We used multivariable logistic regression and generalized estimating equations to identify factors independently associated with antipsychotic receipt. RESULTS: Overall, 948/3692(25.7%) residents received an antipsychotic, of which 59.3% had an evidence-based indication for use. Residents with aggressive behavior [odds ratio (OR)=2.74, 95% confidence interval (CI), 2.04-3.67] and polypharmacy (9+ drugs; OR=1.84, 95% CI, 1.41-2.40) were more likely to receive antipsychotics, as were users of antidepressants (OR=1.37, 95% CI, 1.14-1.66), anxiolytic/hypnotics (OR=2.30, 95% CI, 1.64-3.23), or drugs for dementia (OR=1.52, 95% CI, 1.21-1.92). Those residing in Alzheimer/dementia special care units were also more likely to receive an antipsychotic (OR=1.66, 95% CI, 1.26-2.21). Veterans with dementia but no documented psychosis were as likely as those with an evidence-based indication to receive an antipsychotic (OR=1.10, 95% CI, 0.82-1.47). CONCLUSIONS: Antipsychotic use is common among VA nursing home residents aged 65 and older, including those without a documented evidence-based indication for use. Further quality improvement efforts are needed to reduce potentially inappropriate antipsychotic prescribing.
Authors: Lon S Schneider; Pierre N Tariot; Karen S Dagerman; Sonia M Davis; John K Hsiao; M Saleem Ismail; Barry D Lebowitz; Constantine G Lyketsos; J Michael Ryan; T Scott Stroup; David L Sultzer; Daniel Weintraub; Jeffrey A Lieberman Journal: N Engl J Med Date: 2006-10-12 Impact factor: 91.245
Authors: Dustin D French; Robert R Campbell; Andrea M Spehar; Laurence Z Rubenstein; Francesca E Cunningham Journal: J Am Med Dir Assoc Date: 2007-09-17 Impact factor: 4.669
Authors: Mary E Plomondon; P Michael Ho; Li Wang; Gwendolyn T Greiner; James H Shore; Joseph T Sakai; Stephan D Fihn; John S Rumsfeld Journal: BMC Health Serv Res Date: 2007-09-18 Impact factor: 2.655
Authors: Camilla B Pimentel; Jennifer L Donovan; Terry S Field; Jerry H Gurwitz; Leslie R Harrold; Abir O Kanaan; Celeste A Lemay; Kathleen M Mazor; Jennifer Tjia; Becky A Briesacher Journal: J Am Geriatr Soc Date: 2015-02 Impact factor: 5.562
Authors: Joseph T Hanlon; Sherrie L Aspinall; Steven M Handler; Walid F Gellad; Roslyn A Stone; Todd P Semla; Mary Jo V Pugh; Maurice W Dysken Journal: Ann Pharmacother Date: 2014-11-07 Impact factor: 3.154
Authors: Sherrie L Aspinall; Xinhua Zhao; Todd P Semla; Francesca E Cunningham; Allison M Paquin; Mary Jo Pugh; Kenneth E Schmader; Roslyn A Stone; Joseph T Hanlon Journal: J Am Geriatr Soc Date: 2014-12-23 Impact factor: 5.562
Authors: Stephanie K Nothelle; Ritu Sharma; Allison H Oakes; Madeline Jackson; Jodi B Segal Journal: J Am Med Dir Assoc Date: 2017-07-29 Impact factor: 4.669
Authors: Glen I Spielmans; Margit I Berman; Eftihia Linardatos; Nicholas Z Rosenlicht; Angela Perry; Alexander C Tsai Journal: PLoS Med Date: 2013-03-12 Impact factor: 11.069
Authors: Andrea Foebel; Anna Ballokova; Nathalie I H Wellens; Daniela Fialova; Koen Milisen; Rosa Liperoti; John P Hirdes Journal: BMC Geriatr Date: 2015-10-19 Impact factor: 3.921
Authors: Joshua M Thorpe; Carolyn T Thorpe; Walid F Gellad; Chester B Good; Joseph T Hanlon; Maria K Mor; John R Pleis; Loren J Schleiden; Courtney Harold Van Houtven Journal: Ann Intern Med Date: 2016-12-06 Impact factor: 25.391